<DOC>
	<DOCNO>NCT01101334</DOCNO>
	<brief_summary>This Phase 2 open-label ( subject know treatment receive ) study . The subject receive either Erlotinib alone Erlotinib + CS-7017 study . The study determine effect add CS-7017 Erlotinib safety length survival subject advance non-small cell lung cancer fail first treatment .</brief_summary>
	<brief_title>Study Erlotinib With Without Investigational Drug ( CS-7017 ) Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB IV NSCLC . Recurrent disease ( either response treatment subsequent relapse objective response ) progress first line therapy . Measurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) Version 1.1 criterion . ≥ 18 year age . ECOG performance status 0 , 1 , 2 . Adequate organ bone marrow function . Resolution toxic effect prior therapy ( except alopecia ) National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) , Version 4.0 grade ≤ 1 . Agreement use effective contraception treatment least 3 month end treatment . No treatment anticancer therapy within 4 week study treatment . No therapeutic palliative radiation therapy major surgery within 4 week study treatment ( except radiotherapy brain metastasis ) . No administration thiazolidinediones ( TZDs ) within 4 week study treatment . No current need concomitant use TZDs study . No uncontrolled infection require IV antibiotic , antiviral , antifungal , know human immunodeficiency virus ( HIV ) infection , active hepatitis B C infection time screen . No history follow condition within 6 month initiate study treatment : diabetes mellitus require treatment insulin TZD agent ; myocardial infarction significant impairment cardiac function ; severe/unstable angina pectoris ; coronary/peripheral artery bypass graft ; New York Heart Association ( NYHA ) class III IV congestive heart failure ; malabsorption syndrome , chronic diarrhea ( last &gt; 4 week ) , inflammatory bowel disease , partial bowel obstruction . No pericardial pleural effusion ( eg , require drainage ) pericardial involvement tumor . Subjects minimal pleural effusion may eligible upon request Investigator approval Sponsor . Neither pregnant breast feeding . No known EGFR mutation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NSCLC</keyword>
</DOC>